Fetroja (cefiderocol) / Shionogi  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fetroja (cefiderocol) / Shionogi
APEKS-cUTI, NCT02321800 / 2014-000914-76: A Study of Efficacy and Safety of Intravenous Cefiderocol (S-649266) Versus Imipenem/Cilastatin in Complicated Urinary Tract Infections

Completed
2
452
NA
Cefiderocol, FETROJA®, S-649266, Imipenem/cilastatin, PRIMAXIN®
Shionogi
Urinary Tract Infections
07/16
08/16
NCT04335539 / 2019-002120-32: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Cefiderocol in Hospitalized Pediatric Participants

Completed
2
54
Europe, RoW
Cefiderocol, S-649266, Fetroja, Standard of Care
Shionogi
Gram-negative Bacterial Infections, Bloodstream Infections (BSI), Complicated Intra-abdominal Infection (cIAI), Hospital Acquired Pneumonia (HAP), Ventilator-acquired Pneumonia, Complicated Urinary Tract Infection (cUTI), Sepsis
02/23
02/23
GAMECHANGER, NCT03869437: RCT Cefiderocol vs BAT for Treatment of Gram Negative BSI

Completed
2
513
RoW
Cefiderocol, S-649266, Best Available Therapy
The University of Queensland, Shionogi
Bloodstream Infections
11/23
01/24
NCT06086626: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

Recruiting
2
40
US, RoW
Cefiderocol, S-649266, Standard of Care
Shionogi
Gram-Negative Bacterial Infections
12/24
12/24
NCT04215991 / 2019-002121-30: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants

Active, not recruiting
2
84
Europe, US, RoW
Cefiderocol, Fetroja, S-649266, Standard of Care
Shionogi
Gram-negative Bacterial Infections, Hospital Acquired Bacterial Pneumonia (HABP), Complicated Urinary Tract Infection (cUTI), Ventilator Associated Bacterial Pneumonia (VABP)
09/24
09/24

Download Options